|Barclays Private Equity acquires fine chemical specialist CU UETIKON in Germany from the Swiss CPH Chemie + Papier Holding.|
|Target Company Name||CU Uetikon GmbH|
|Buyer Name / MBO Team / MBI Team||Barclays Private Equity|
|Buyer Country||United Kingdom|
Barclays Private Equity (‘BPE’) acquires a majority shareholding of the Fine Chemical specialist CU Chemie UETIKON GmbH (‘CU UETIKON’) based in Lahr, Germany. With a shareholding of 90 percent, BPE will have a controlling interest in the spin-off from the Swiss group CPH Chemie + Papier Holding AG (CPHN:SE). Together with management, BPE will pursue a consistent growth strategy in pharmaceuticals, cosmetics and nutrition industries. The consideration is undisclosed.
CU UETIKON is an established manufacturer of Fine Chemicals and Active Pharmaceutical Ingredients and has been operating from its site in Lahr in the German Black Forest for over 40 years. The company develops Custom Synthesis of complex multilevel intermediaries and Active Pharmaceutical Ingredients (APIs), focussing on niche therapeutic markets and Fine Chemicals for the nutrition and cosmetics industries amongst others. CU UETIKON owns one of the most advanced production facilities in the world, which complies with all Good Manufacturing Practice (GMP) industry guidelines, ensuring consistently high quality production processes. Furthermore, CU UETIKON is regularly tested by national and international health authorities, in particular the United States Food and Drug Administration (FDA) for which it has passed every audit to date.
|ICFG Office||Zurich: Ramus & Company, Switzerland|
|ICFG Advisory||ICFG Zurich and Lazard advised the seller in 2011.|